SCHEMBL3873064

SCHEMBL3873064

CC(C)(C)OC(=O)CCNc1nc(Cl)ncc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 2/20 0.53
STK17A Q9UEE5 2/20 0.53
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 1/20 0.34
TLR8 Q9NR97 1/20 0.34
SYK P43405 1/20 0.33
PI4KA P42356 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
TBK1 Q9UHD2 1/20 0.33
SIRT5 Q9NXA8 1/20 0.33
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
MAPK10 P53779 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CCNB2 O95067 1/20 0.32
CCNE2 O96020 1/20 0.32
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CCNB1 P14635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2723366 0.84 STK17B (0.67) STK17BSTK17AMEN1KMT2AFPR3
SCHEMBL3868126 0.82 STK17B (0.79) STK17BSTK17AMEN1KMT2AFPR3
SCHEMBL27635199 0.80 SIRT5 (0.46) STK17BSTK17AMEN1KMT2ASIRT5
SCHEMBL13649013 0.80 STK17B (0.46) STK17BSTK17AMEN1KMT2AMAPT
SCHEMBL31424919 0.79 STK17A (0.53) STK17BSTK17AMEN1KMT2ASYK
SCHEMBL17162031 0.79 STK17A (0.53) STK17BSTK17AMEN1KMT2ASYK
SCHEMBL3450121 0.79 STK17B (0.40) STK17BSTK17AMEN1KMT2ASYK
SCHEMBL2816189 0.77 STK17B (0.39) STK17BSTK17AMEN1KMT2ACCNB2
SCHEMBL17169968 0.75 STK17B (0.53) STK17BSTK17AMEN1KMT2AMAPT
SCHEMBL1774178 0.75 GLP1R (0.45) STK17BSTK17AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 US disclosed
CN-1717396-A Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AG (DE) 2006-01-04 CN disclosed
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents DCK, PDPK1, DTYMK STK17B 247/4885STK17A 226/4885MEN1 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.